|
|
|
|
| LEADER |
03802nmm a2200265 u 4500 |
| 001 |
EB000712046 |
| 003 |
EBX01000000000000000565128 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9789400932876
|
| 100 |
1 |
|
|a van der Wall, Ernst E.
|e [editor]
|
| 245 |
0 |
0 |
|a Noninvasive Imaging of Cardiac Metabolism
|h Elektronische Ressource
|b Single Photon Scintigraphy, Positron Emission Tomography and Nuclear Magnetic Resonance
|c edited by Ernst E. van der Wall
|
| 250 |
|
|
|a 1st ed. 1987
|
| 260 |
|
|
|a Dordrecht
|b Springer Netherlands
|c 1987, 1987
|
| 300 |
|
|
|a XVI, 311 p
|b online resource
|
| 505 |
0 |
|
|a 1. Radiopharmaceuticals for cardiovascular nuclear medicine -- 2. Myocardial imaging with radiolabeled free fatty acids: current views -- 3. Chain-modified radioiodinated fatty acids -- 4. Uptake and distribution of radioiodinated free fatty acids in the dog heart -- 5. Iodinated free fatty acids: reappraisal of methodology -- 6. Experimental studies on myocardial metabolism of iodinated fatty acids: a proposal for a new curve analysis technique -- 7. Radioiodinated free fatty acids: a clue to myocardial metabolism? -- 8. Cardiac metabolism of I-123 phenyl-pentadecanoic acid -- 9. The development of radioiodinated 3-methyl-branched fatty acids for evaluation of myocardial disease by single photon techniques -- 10. Progress in cardiac positron emission tomography with emphasis on carbon-11 labeled palmitate and oxygen- 15 labeled water -- 11. Assessment of glucose utilization in normal and ischemic myocardium with positron emission tomography and 18F-deoxyglucose -- 12. Nuclear magnetic resonance spectroscopy in experimental cardiology -- 13. Nuclear magnetic resonance spectroscopy: its present and future application to studies of myocardial metabolism -- 14. Metabolic imaging: PET or NMR -- Index of subjects
|
| 653 |
|
|
|a Cardiology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a Developments in Cardiovascular Medicine
|
| 028 |
5 |
0 |
|a 10.1007/978-94-009-3287-6
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-94-009-3287-6?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.12
|
| 520 |
|
|
|a F.J.Th. WACKERS Metabolic imaging: The future of cardiovascular nuclear imaging? Since cardiovascular nuclear imaging emerged as a new subspecialty in the mid-1970s, the field has gone through an explosive growth. Radionuclide techniques became readily recognized as important new diagnostic aids in the armamentarium of the clinical cardiologist. Initially, cardiovascular nuclear imaging focused on static myocardial imaging using either thallium-201 or technetium-99m-pyrophosphate for diagnosing acute myocardial infarction. Shortly thereafter, multigated equilibrium radionuclide angiocardiography became the most widely used noninvasive method for assessing cardiac function. Furthermore, attention and clinical application shifted towards the use of radionuclide techniques in conjunction with exercise testing, either with thallium-20 1 myocardial perfusion imaging or technetium-99m left ventricular function studies. The future of cardiovascular nuclear imaging appeared exciting and promising. However, around 1980 pessimists predicted the premature demise of cardiovascular nuclear imaging with the introduction of digital subtraction angiography and nuclear magnetic resonance imaging. These doomsayers have been proven wrong: in 1985 cardiovascular nuclear imaging is thriving and, in many centers, even expanding. Although digital substraction angiography and magnetic resonance imaging provided exquisite anatomic detail, for practical evaluation of patients with ischemic heart disease - in the Coronary Care Unit or exercise laboratory - nuclear techniques appeared to be more practical
|